TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06282861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol stada
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxis
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formatris
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Aldo
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onbrez
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oslif
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hirobriz
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Striverdi
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beglan
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamican
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inaspir
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serevent
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soltel
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eklira
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bretaris
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seebri
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tovanor
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enurev
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tavulus
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirkava
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Braltus
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gregal
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incruse
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rolufta
Description: As per product specifications
Study: NCT05807373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: voice recordings
Description: A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: voice recordings
Description: A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: voice recordings
Description: A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice)
Study: NCT04650295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Household Remedy
Description: If the participant experiences a muscle cramp one tablespoon (one sip) of the household product will be taken. The treatment phase of the study will be for 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tap water
Description: If the participant experiences a muscle cramp one tablespoon (one sip) of tap water will be taken. The treatment phase of the study will be for 28 days.
Study: NCT06266000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saw palmetto extract 320mg per day
Description: Saw palmetto extract 160mg per capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Saw palmetto extract 320mg per day
Description: Saw palmetto extract 160mg per capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palm Oil capsule
Description: Palm oil capsule
Study: NCT06495892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretic therapy
Description: Diuretic therapy will be tailored according to peripheral venous pressure targets or standard approach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretic therapy
Description: Diuretic therapy will be tailored according to peripheral venous pressure targets or standard approach
Study: NCT05920174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEO
Description: Subjects will be implanted with the NEO device.
Study: NCT05497895

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Only SRP-one stage prophylaxis
Description: The Group III patients will be subjected to one-stage oral prophylaxis.
Study: NCT04792190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin
Description: Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily, for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 1 blinded capsule of placebo drug dosed once daily
Study: NCT06510816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX007
Description: Form: solution for injection; Route of Administration: IVT injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Administration
Description: Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection).
Study: NCT05653700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arena Strive
Description: This second-generation platform provides frontline clinicians with a comprehensive journey to access the tools, training, and technology used by other high-pressure fields to increase performance and enhance resilience. The experimental intervention employed in this study will be a 12-week, multi-phased approach involving an asynchronous learning and coaching experience (6 weeks), and exploration phase (6 weeks).

Intervention type: OTHER
Group type: OTHER
Intervention: Control Cohort
Description: Participants randomized into the control cohort - survey at baseline and end of the study
Study: NCT04945824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic
Description: Insertion Device: A handheld mechanical device used by the clinician to dilate the punctum and deliver the DEXTENZA insert into the canaliculus; designed to be single-use and pre-loaded with a single DEXTENZA insert.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilator
Description: Intracanalicular Dilator Device
Study: NCT05480254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clamped catheter
Description: Q3 clamped catheter protocol is applied before urinary catheter removal
Study: NCT05482282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis B new Bulk vaccine
Description: 1 dose of Recombinant Hepatitis B vaccine using new Hepatitis B bulk (Bio Farma)~1 dose of 0.5 ml Recombinant Hepatitis B new Bulk vaccine dose of DTP-HB-Hib using new Hepatitis B Bulk vaccine injected intramuscularly into the left external antero-lateral thigh region.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine
Description: 3 doses of DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis B vaccine (Registered BioFarma)
Description: 1 dose of Recombinant Hepatitis B vaccine (Registered Bio Farma)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentabio
Description: 3 doses of Pentabio
Study: NCT06394284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA-AT
Description: As described above in arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEA-IT
Description: As described in arm description
Study: NCT05437393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Deep brain stimulation of the centromedian nucleus (bilateral)
Study: NCT05704439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurologist Initiated Treatment
Description: Neurologist Initiated Treatment for Hypertension or Hyperlipidemia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Usual care
Study: NCT06322706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK021
Description: ABSK021 oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK021
Description: ABSK021 oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole oral
Study: NCT05216068

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NGS
Description: Based on the next generation sequencing (NGS), WES can identify single nucleotide variants (SNVs) and small variants.
Study: NCT05690334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid - 0 ml/kg
Description: No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid - 5 ml/kg
Description: 5 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid - 10 ml/kg
Description: 10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT05875376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple group therapy
Description: 1. Introduction of I statements~2. Focus of each conversation~3. Emotion acknowledgement~4. Self-assurance and positive feedback~5. teamwork and cooperation~6. Reflection
Study: NCT05918224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius K12
Description: The patients in intervention group were treated with Streptococcus salivarius K12 lozenges three times a day after gargling from the first day of radiotherapy up to 1 week after the end of treatment. Streptococcus salivarius K12 is dissolved in the mouth and then swallowed.
Study: NCT05530278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galicaftor
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galicaftor
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galicaftor
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-576
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-576
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-576
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-576
Description: Oral
Study: NCT05918224

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Streptococcus salivarius K12 simulants
Description: Patients in control group were treated with Streptococcus salivarius K12 simulants, and its use method and use time are the same as intervention group.
Study: NCT05530278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-576
Description: Oral
Study: NCT05371431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation training
Description: The non-BFR group undertook traditional rehabilitation training only. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction combined with traditional rehabilitation training
Description: BFR group completed the traditional rehabilitation training with a medical grade tourniquet applied on the upper arm. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
Study: NCT05847439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]BMS-986419
Description: Specified dose on specified days
Study: NCT05355714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: High-Frequency Non-Focused Ultrasound Device

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultherapy
Description: Microfocused Ultrasound with Visualization
Study: NCT05530278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navocaftor
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navocaftor
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navocaftor
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navocaftor
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral
Study: NCT05157399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otoband
Description: Participants with Dizziness and Vertigo will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Device
Description: Participants with Dizziness and Vertigo will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
Study: NCT06246253

Intervention type: PROCEDURE
Intervention: Virtual implant placement following safe angle concept
Description: Virtual implant placement following safe angle concept in anterior maxillary teeth.

Intervention type: PROCEDURE
Intervention: actual implant placement following safe angle concept
Description: actual implant placement following safe angle concept in anterior maxillary teeth
Study: NCT06488924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-446
Description: IV infusion
Study: NCT06160323

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided coeliac ganglion neurolysis / celiac plexus neurolysis
Description: The EUS scope was first inserted into the stomach, and the coeliac trunk was visualized by scanning from the lesser curve of the gastric body. After visualization, the scope was rotated clockwise, enabling visualization and identification of the left adrenal gland. The coeliac ganglia are often seen to the left of the coeliac artery, between the aorta and the left adrenal gland, at the level between the coeliac artery and the left adrenal artery. They are also visualized cephalad to the coeliac artery in some cases. Hypoechoic nodular structures linked by hypoechoic threads residing in the periphery of this region were defined as the coeliac ganglia . A 19G or 22G needle was used for puncture of the CGN. After confirming the lack of backflow of blood with aspiration, a mixture of 5ml of 0.25-0.5% bupivacaine and 5ml absolute alcohol was injected.~For cases in which celiac ganglia could not be visualized, EUS-guided coeliac plexus neurolysis (CPN) will be performed.
Study: NCT06143813

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Selective nerve root block (SNRB)
Description: CT/Fluoroscopy guided nerve root block
Study: NCT05964179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: time extended feeding
Description: Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 14 hours per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: time restricted feeding
Description: Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 8 hours per day.
Study: NCT05932173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 Autologous CAR-T Cell Infusion
Description: Autologous T cells modified with anti-CD19 ScFv expression and manufactured by OlyCAR platform
Study: NCT05566938

Intervention type: OTHER
Group type: OTHER
Intervention: Tailored nutritional recommendations for each metabotype
Description: Tailored nutritional recommendations for each metabotype detected (at the group level), that will be delivered through a mobile application. Moreover, each volunteer will recieve individualized nutritional recommendations.
Study: NCT06589713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran
Description: Participants will receive a single oral dose of enpataron tablets once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran
Description: Participants will receive a single oral dose of enpataron tablets once daily.
Study: NCT06669455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized and combined lifestyle approach
Description: In the SENSS approach five different and complementary lifestyle domains (self-management, exercise, nutrition, sleep and stress) are combined. The process will be guided by a lifestyle coach. The intervention is personalised for each participant. The personal goals are decided based on 'shared decision making' together with the lifestyle coach after using a Parkinson lifestyle decision aid. The level of guidance needed throughout the intervention is based on a 'stepped care approach'.
Study: NCT06452732

Intervention type: OTHER
Intervention: MFC for the determination of leukemia stem cell
Description: MFC for the determination of leukemia stem cell
Study: NCT06674473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With robot assistance
Description: Use a portable isokinetic device

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional bodyweight rehabilitation
Description: Use traditional bodyweight rehabilitation
Study: NCT05883202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connect®
Description: Restoration of multiple implants with a Connect® abutment between the implant and the prosthesis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-unit
Description: Restoration of multiple implants with a conventional multi-unit abutment between the implant and the prosthesis.
Study: NCT05859139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DA Scaling Strategies
Description: For this study the intervention will consist of different DA scaling strategies : 1) dissemination of an online DA; 2) dissemination of a paper-based DA; 3) online training for healthcare professionals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DA Scaling Strategies
Description: For this study the intervention will consist of different DA scaling strategies : 1) dissemination of an online DA; 2) dissemination of a paper-based DA; 3) online training for healthcare professionals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DA Scaling Strategies
Description: For this study the intervention will consist of different DA scaling strategies : 1) dissemination of an online DA; 2) dissemination of a paper-based DA; 3) online training for healthcare professionals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DA Scaling Strategies
Description: For this study the intervention will consist of different DA scaling strategies : 1) dissemination of an online DA; 2) dissemination of a paper-based DA; 3) online training for healthcare professionals.
Study: NCT06690775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-1-23
Description: 2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-1-23
Description: 3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-1-23
Description: 3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (drug)
Description: 6 mg subcutaneous injection on Day 4 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (drug)
Description: 6 mg subcutaneous injection on Day 4 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (drug)
Description: 6 mg subcutaneous injection on Day 4 of each cycle.
Study: NCT06717035

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EYE001
Description: Defocus incorporated multiple segments (DIMS) clear vs DIMS photochromic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EYE001
Description: Defocus incorporated multiple segments (DIMS) clear vs DIMS photochromic
Study: NCT06713538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equine assisted therapy
Description: The intervention will last for 12 sessions, with two 1.5-hour sessions per week. The program is offered to patients in addition to their usual daily schedule. These 12 sessions will be organized as follows:

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: The subjects will independently carry out 12 sessions (2 sessions of 90 minutes per week for 6 weeks) of moderate-intensity physical activity. The endurance activity should be performed according to the patient's capabilities and fatigue levels.